Regulatory requirements shift constantly, across every geography your pipeline touches, and the cost of missing a relevant precedent, guidance update, or competitor filing isn't measured in inconvenience, it's measured in delayed submissions and lost negotiating leverage. Most teams are still trying to keep up with pharmaceutical regulatory intelligence through fragmented searches across disconnected databases, general web search, and institutional memory that walks out the door when someone leaves. Dr. Evidence is the pharma regulatory intelligence platform built to close that gap: one place to find precedent, track competitors, and build regulatory strategy on evidence instead of guesswork.
Every regulatory strategy starts with a question: what has already been accepted? Dr. Evidence gives your team fast, comprehensive access to approval packages, guidance documents, and global labels across a wide breadth of geographies, so your regulatory intelligence tool doesn't just search; it surfaces the precedent that actually matters. What used to take a regulatory affairs team weeks of manual document review now takes hours, freeing your team to spend its time on strategy instead of search.
Regulatory intelligence isn't only about your own submissions. It's about knowing what everyone else in your space is doing before it affects your plans. Dr. Evidence automates tracking of competitor submissions and approvals, replacing the manual monitoring that leaves teams perpetually one step behind. Instead of discovering a competitor's approval after the fact, your team gets ahead of it. (For a deeper, label-level view of competitor strategy — indications, safety language, and dosing comparisons — visit our Competitive Intelligence page.)
At the center of the platform is Dr. Evidence's purpose-built technology to synthesize intelligence across the full regulatory landscape, allowing users to summarize documents, connect precedent, monitor competitor activity, and access guidance into a coherent strategic picture. Unlike general AI tools, these models are trained exclusively on authoritative, verified regulatory content, which means no hallucinated citations and no invented precedent in a space where accuracy isn't optional. Every output is Human-in-Command by design: your team stays in control of the strategy, with the platform providing the evidence and the traceability to back it up. This is regulatory intelligence software built for regulated decisions, not general-purpose AI adapted after the fact.
Regulatory teams that adopt Dr. Evidence consistently point to the same set of outcomes. They accelerate submission and review workflows by working from one unified source instead of a dozen scattered ones. They eliminate the fragmented searching that used to consume entire weeks of a regulatory calendar. They support genuine cross-functional collaboration, because regulatory, labeling, and medical affairs teams are finally working from the same evidence base. They reduce hours of manual research to minutes of AI-assisted synthesis. They gain access to trusted, up-to-date sources instead of static exports that go stale the day they're pulled. They simplify monitoring across global markets that would otherwise require a dedicated tracking effort for every geography. And, ultimately, they report greater confidence in the regulatory and labeling decisions they make because every recommendation is backed by a verifiable source, not an assumption.
Regulatory strategy for drug development doesn't end at approval. It's a continuous discipline that runs from the earliest submission planning through years of post-market label management and lifecycle strategy. Dr. Evidence supports every stage of that lifecycle from a single platform, so your regulatory intelligence services don't reset with every new milestone. Global regulatory intelligence teams, and the life science regulatory intelligence and strategy functions that support them, get one source of truth instead of a new tool for every phase.
Walking into a health authority meeting without a full view of the landscape is a disadvantage you can't afford. Dr. Evidence gives your team the intelligence to anticipate how a health authority is likely to respond, based on what they've accepted before, and to prepare evidence-backed arguments rather than reactive ones. That's the difference between a negotiation your team drives and one your team simply survives.
Regulatory strategy built on precedent, not guesswork, is the advantage your team has been missing.
Book a Demo to see Dr. Evidence's pharma labeling software in action to see exactly how it works.